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Abstract: Cystine-knot miniproteins (CKMPs) are an intriguing group of cysteine-rich molecules that
combine the characteristics of proteins and peptides. Typically, CKMPs are fewer than 50 residues in
length and share a characteristic knotted scaffold characterized by the presence of three intramolecular
disulﬁde bonds that form the singular knotted structure. The knot scaffold confers on these
proteins remarkable chemical, thermal, and proteolytic stability. Recently, CKMPs have emerged
as a novel class of natural molecules with interesting pharmacological properties. In the present
work, a novel cystine-knot metallocarboxypeptidase inhibitor (chuPCI) was isolated from tubers of
Solanum tuberosum, subsp. andigenum cv. Churqueña. Our results demonstrated that chuPCI is a
member of the A/B-type family of metallocarboxypeptidases inhibitors. chuPCI was expressed and
characterized by a combination of biochemical and mass spectrometric techniques. Direct comparison
of the MALDI-TOF mass spectra for the native and recombinant molecules allowed us to conﬁrm the
presence of four different forms of chuPCI in the tubers. The majority of such forms have a molecular
weight of 4309 Da and contain a cyclized Gln in the N-terminus. The other three forms are derived
from N-terminal and/or C-terminal proteolytic cleavages. Taken together, our results contribute to
increase the current repertoire of natural CKMPs.
Keywords: cystine-knot miniproteins; carboxypeptidase inhibitor; plant inhibitor; Solanum tuberosum;
protease; Andean potatoes
1. Introduction
Cystine-knot miniproteins (CKMPs or “knottins”) have recently emerged as a novel natural class
of biomolecules with unique structural and functional properties [1,2]. CKMPs combine characteristics
from proteins and peptides, displaying a protein-like fold but having a peptide-like size (>10 kDa) [1–3].
Typically, these molecules are 30–50 amino acids in length and share a common extremely stable
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tertiary fold, the so-called cystine-knot motif. This motif is formed of three antiparallelβ-strands and
connecting loops of varying length and amino acid composition. The whole knot structure (also termed
the knottin scaffold) is held together by a characteristic disulﬁde-bridge connectivity composed of
three disulﬁde bridges, which endows the resulting molecule with exceptional thermal, chemical, and
proteolytic stability [1,2,4].
To date, a large number of CKMPs have been identiﬁed and isolated from natural sources
(i.e., from arthropods, vertebrates, mollusks, fungi, plants, and so on). These molecules belong to more
than 34 protein families and are involved in diverse biological functions [1,2]. In animals, CKMPs
are secreted peptides that function as extracellular signaling molecules involved in the regulation
of important cellular functions such as cell growth or cell development [5,6]. In plants, CKMPs
are often involved in defense against external pathogens. Typically, the latter group functions as
protease inhibitors and/or modulators of responses against pathogen attack [5,7,8]. Due to their
extremely high stability, resistance to proteolysis, and interesting pharmacological properties, many
natural CKMPs have gained much attention as novel peptide-based drugs for the treatment of a
wide range of relevant human diseases such as chronic pain, infections, malaria, or ischemic strokes,
among others [1]. One of the most prominent examples is the case of the calcium channel blocker
ω-conotoxin MVIIa from the marine snail Conus magus. This cystine-knot miniprotein has recently
been approved by FDA for the treatment of severe chronic pain [1,9]. Other relevant examples are the
spider toxins Psalmopeotoxin I and II, which have been shown potent antiplasmodial activity against
the malaria parasite Plasmodium falciparum [10,11]. Interestingly, several CKMPs isolated from plants
(e.g., Pafp-S, circulin A, circulin B, cyclopsychotride, or kalata B1) have demonstrated antibacterial
and/or antifungal activities [3,12–14].
A number of CKMPs function as potent protease peptide inhibitors (PPIs). Among them, the potato
carboxypeptidase inhibitor (PCI) was the first CKMPs to be discovered [4]. In particular, PCI inhibits
different enzymes within the family of metallocarboxypeptidases (MCPs), proteolitic enzymes that
cleave C-terminal amino acids in proteins and peptides [15,16]. The first crystal structure of this 39 amino
acid plant protease inhibitor was reported in 1980 by Rees and Liscomb [ 17]. After almost 40 years of
intense research in the field of proteases, only a small number of metallocarboxypeptidase inhibitors
(MCPIs) have been isolated and characterized so far [18–29]. Some of those novel PPIs are cystine-knot
miniproteins isolated from species of the Solanaceae family of flowering plants, i.e., Solanum tuberosum
(PCI), Solanum lycopersicum (MPCI) [18], Capsicum annuum (YBPCI) [29] and the variety of Andean
potatoes Solanum tuberosum, subsp. andigenum cv. Imilla morada (imaPCI) [20]. In addition, other naturally
occurring MCPIs without a knottin fold have been isolated from different animal species such as
the intestinal parasite Ascaris suum (ACI) [30]; the medicinal leech Hirudo medicinalis (LCI) [23];
the tick Rhipicephalus bursa (TCI) [24] and Hemaphysalis longicornis (H1TCI) [25]; the marine mollusk
Nerita versicolor (NvCI) [28], the marine ringworm Sabellastarte magnifica (SmCI) [31]; and rats and
humans (i.e., latexin and its close homolog RARES-1). The use of natural PPIs to regulate MCPs’
action has emerged as a potential tool for the development of new therapeutic strategies. This is in
agreement with the hypothesis that natural products will be among the most important sources of
new bioactive drugs in the future [32,33]. In 2006 Wang and co-workers demonstrated that PCI can act
as an antithrombotic drug [34]. Moreover, PCI was demonstrated to inhibit in vitro adenocarcinoma
cell growth by acting as an epidermal growth factor (EGF) antagonist [35]. More recently, it has been
demonstrated that the same inhibitor blocks the C-terminal cleavage (and consequent inactivation) of
human EGF in vitro by the pancreatic carboxypeptidases A and B (CPA and CPB, respectively) [20].
Here we show the identification of a novel cystine-knot miniprotein, a member of the PCI-family
present in S. tuberosum subsp. andigenum cv. Churqueña, a variety of potato cultivated along the
Andean Cordillera in South America. This novel inhibitor, named chuPCI, was isolated from
potato tubers, purified by affinity chromatography, and further characterized by matrix-assisted laser
desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry. The total RNA isolated from
the tuber buds was employed for the cloning and expression of this novel inhibitor. The resultant
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recombinant product (rchuPCI) was purified until homogeneity and further characterized using mass
spectrometry. Finally, the Ki values were determined against bovine CPA (bCPA) and porcine CPB
(pCPB), two pancreatic MCPs. This work expands the current knowledge of CKMPs present in potatoes,
one of the most cultivated and consumed crops all over the world.
2. Results and Discussion
2.1. Identiﬁcation and Initial Characterization of a Native Metallocarboxypeptidase Inhibitor from S. tuberosum
subsp. andigenum cv. Churqueña
Members of the Solanaceae family of ﬂowering plants are considered one of the most important
sources of metallocarboxypeptidase inhibitors. In our study, we investigated the presence of
carboxypeptidase inhibitors in an uncharacterized variety of potatoes; the S. tuberosum subsp.
andigenum cv. Churqueña. This variety of Andean potatoes is endemic to the Andean Cordillera
in South America, where it is extensively cultivated following local agro-ecological conditions. Several
kilograms of fresh potato tubers were acquired from local growers. This material was used to prepare
a crude extract achieved by crushing the tubers in distilled water. The resultant homogenate was
incubated and centrifuged until we obtained a clear crude extract containing a large amount of
the carboxypeptidase inhibitor. The total protein concentration of this sample was 790 µg·mL−1.
The presence of the inhibitors in the ﬁnal homogenate was conﬁrmed by performing a dose–response
inhibition experiment, as described previously [36]. The resultant IC50 value was 15.7 µg·mL−1.
This IC50 value is comparable to those found in previous reports for other potato varieties [20,36].
Then, the clariﬁed crude extract was subjected to thermal treatment at 60, 70, 85, and 100 ◦C for
60 min. In previous studies, it was demonstrated that MCPIs are heat-stable molecules due to the
highly stable knottin scaffold [37]. After incubation at the indicated temperatures and centrifugation of
the samples, the analysis of the soluble fraction using Bradford revealed an important reduction
in the total protein content in all the heat-treated conditions (60 ◦C treatment = 112 µg·mL−1,
70 ◦C treatment = 88 µg·mL−1, 85 ◦C treatment = 92 µg·mL−1, 100 ◦C treatment = 82 µg·mL−1) in
comparison with the soluble fraction of the untreated crude extract (CE = 789 µg·mL−1). The loss of
protein content in the heat-treated samples can be explained by the denaturation of those heat-labile
proteins. According to our results, these proteins represent more than 80% of the protein content
when the crude extract was incubated at temperatures of 60 ◦C or higher. Simultaneously, the CPA
inhibitory activity present in each of the samples of the crude extract and heat-treated conditions
was determined (see Figure 1A). Results suggest the presence of a heat-stable CPA inhibitor in the
crude extract. This molecule displayed high temperature stability, even after thermal treatment at
100 ◦C for 60 min (Figure 1A). Therefore, our results demonstrate that heat treatment at relatively high
temperatures (up to 100 ◦C) mainly affects other proteins present in the crude extract, but not such
miniproteins with a speciﬁc carboxypeptidase A inhibitory activity. Moreover, by heating the crude
extract at temperatures higher than 60 ◦C we achieved a partial puriﬁcation of the inhibitor.
Proteins from each heat treatment were analyzed using tris-tricine sodium dodecyl sulfate
polyacrylamide gel electrophoresis (tris-tricine-SDS-PAGE) and stained with Coomassie Blue after the
electrophoresis. As shown in Figure 1B, the crude extract contains a variety of proteins of different
molecular weight. The most abundant bands are those with an apparent molecular weight of around 40,
20, 13, and 4–5 kDa. Interestingly, thermal treatment at 70, 85, and 100 ◦C caused a notorious decrease
in the intensity of those bands with a higher apparent molecular weight (>20 kDa). By contrast, bands
of a lower apparent molecular weight displayed similar intensities after the aforementioned heat
treatments (i.e., bands migrating at a molecular weight less than 14 kDa, and especially the band with
an apparent molecular weight of 5 kDa). These results are in agreement with previous studies in which
it was demonstrated that low molecular weight protease inhibitors are stable at high temperatures [23].
The isoelectric points (Ip) of all the proteins present in the crude extract and in the heat-treated samples
were investigated by isoelectric focusing. The resultant isoelectrofocusing proﬁles showed the presence
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of a major band with an Ip of around 4.5 (Figure 1C). This Ip is comparable to what was previously
described for potato carboxypeptidase inhibitors isolated from other potato varieties [20].
Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  4 of 19 
 
1C). This Ip is comparable to what was previously described for potato carboxypeptidase inhibitors 
isolated from other potato varieties [20]. 
 
Figure 1. Thermal stability characterization of the Churqueña tubers crude extract. (A) 
Carboxypeptidase A (CPA) inhibitory activity of the non-treated crude extract (CE) and of the 
samples of the crude extract after incubation at (T70) 70, (T85) 85 and (T100) 100 °C for 60 min. The 
inhibitory activity of these samples is shown as % compared to (CTRL) a positive control condition of 
CPA without inhibitor; (B) Tris-tricine sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(tris-tricine-SDS-PAGE) analysis of the crude extract (EC) and of the heat-treated samples after 
incubation at (T60) 60, (T70) 70, (T85) 85 and (T100) 100 °C for 60 min; (C) Isoelectrophocusing 
experiment of the crude extract (EC) and heat-treated samples incubated at (T60) 60, (T70) 70, (T85) 
85 and (T100) 100 °C for 60 min. In panels (B,C) equal volumes (25 μL) of each sample were loaded in 
the gel, and the location of the potential S. tuberosum subsp. andigenum cv. Churqueña (native 
chuPCI) carboxypeptidase inhibitor is indicated with an arrow. 
2.2. Purification and MALDI-TOF Mass Spectrometric Analysis of the Native Carboxypeptidase Inhibitor 
MALDI-TOF mass spectrometric analysis of the crude extract and heat-treated samples (ut 
supra) revealed the presence in all the samples of one major peak corresponding to a miniprotein 
with a molecular mass of 4309 Da (Figure S1). This molecular weight mass is close to the expected 
molecular mass of the canonical potato carboxypeptidase inhibitor present in other varieties of 
potato tubers (4295 Da) [20,38]. As shown in Figure S1, this peak was observed practically unaltered 
in all the heat-treated samples (Figure S1). This result is in agreement with our previous results from 
inhibitory activity determinations and tris-tricine-SDS-PAGE analysis, and confirms that our novel 
miniprotein is a heat-resistant molecule. However, the size discrepancy observed between this 
particular molecule and the canonical PCI (16 Da) suggests that our miniprotein might be a distinct 
inhibitor or have a slightly different amino acid composition. To further study this miniprotein, we 
decided to purify this inhibitor from another batch of S. tuberosum subsp. andigenum cv. Churqueña 
potato tubers. For this purpose, purification of the inhibitor was achieved by performing a two-step 
purification protocol. As the first step, the extract was treated at 100 °C for 60 min for the removal of 
all the heat-labile proteins present in the sample. The second step was affinity chromatography (see 
Figure 2A and Materials and Methods Section 3.5.2 for details). For fast purification, we used an 
in-house fabricated resin by immobilizing bCPA in a glyoxyl agarose support in order to purify all 
the carboxypeptidase inhibitors from a fresh-prepared potato extract. This specific chromatography 
has been used in the past for fast purification of a wide range of carboxypeptidase inhibitors [37]. 
Figure 1. Thermal stability characterization of the Churqueña tubers crude extract. (A) Carboxypeptidase
A (CPA) inhibitory activity of the non-treated crude extract (CE) and of the samples of the crude extract
after incubation at (T70) 70, (T85) 85 and (T100) 100 ◦C for 60 min. The inhibitory activity of these samples
is shown as % compared to (CTRL) a positive control condition of CPA without inhibitor; (B) Tris-tricine
sodium dodecyl sulfate polyacrylamide gel electrophoresis (tris-tricine-SDS-PAGE) analysis of the crude
extract (EC) and of the heat-treated samples after incubation at (T60) 60, (T70) 70, (T85) 85 and (T100)
100 ◦C for 60 min; (C) Isoelectrophocusing experiment of the crude extract (EC) and heat-treated samples
incubated at (T60) 60, (T70) 70, (T85) 85 and (T100) 100 ◦C for 60min. In panels (B,C) equal volumes (25 µL)
of each sample were loaded in the gel, and the location of the potential S. tuberosum subsp. andigenum cv.
Churqueña (native chuPCI) carboxypeptidase inhibitor is indicated with an arrow.
2.2. Puriﬁcation and MALDI-TOF Mass Spectrometric Analysis of the Native Carboxypeptidase Inhibitor
MALDI-TOF mass spectrometric analysis of the crude extract and h at-treated samples (ut supra)
revealed the presence in all the samples of one major peak corresponding to a miniprotein with a
molecular mass of 4309 Da (Figure S1). This molecular weight mass is close to the expected molecular
mass of the canonical potato carboxypeptidase inhibitor present in other varieties of potato tubers
(4295 Da) [20,38]. As shown in Figure S1, this peak was observed practically unaltered in all the
heat-treated samples (Figure S1). This result is in agreement with our previous results from inhibitory
activity determinations and tris-tricine-SDS-PAGE analysis, and conﬁrms that our novel miniprotein is
a heat-resistant molecule. However, the size discrepancy observed between this particular molecule
and the canonical PCI (16 Da) suggests that our miniprotein might be a distinct inhibitor or have a
slightly different amino acid composition. To further study this miniprotein, we decided to purify this
inhibitor from another batch of S. tuberosum subsp. andigenum cv. Churqueña potato tubers. For this
purpose, puriﬁcation of the inhibitor was achieved by performing a two-step puriﬁcation protocol.
As the ﬁrst step, the extract was treated at 100 ◦C for 60 min for the removal of all the heat-labile
proteins present in the sample. The second step was afﬁnity chromatography (see Figure 2A and
Materials and Methods Section 3.5.2 for details). For fast puriﬁcation, we used an in-house fabricated
resin by immobilizing bCPA in a glyoxyl agarose support in order to purify all the carboxypeptidase
inhibitors from a fresh-prepared potato extract. This speciﬁc chromatography has been used in the past
for fast puriﬁcation of a wide range of carboxypeptidase inhibitors [37]. Protein elution was performed
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under acidic conditions (pH: ~3.0) in order to break the strong interactions that take place between
bCPA and the putative binding molecules (see detailed puriﬁcation protocol in Materials and methods,
Section 3.5.2).
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s sho n in Figure 2B, after puriﬁcation the resultant native iniprotein (hereafter ter ed
native chuP I) could be easily visualized on tris-tricine-SDS-PAGE by Coomassie blue staining, free of
any major contaminating proteins. For further characterization, the initial heat-treated crude extract,
the ﬂow-through (fraction containing the non-retained peptides and proteins), and the elution from
the afﬁnity chromatography containing the ﬁnal puriﬁed protein were subjected to MALDI-TOF mass
spectrometry. A detailed analysis of the peaks present in the mass spectra for the initial heat-treated
crude extract showed the presence of three major peaks (Figure 2C). The two most prominent signals
showed a mass of 3857.1 Da (Ia) and 4310.3 Da (IIIa). The third majoritarian peak showed a mass of
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4198.4 Da (IIa). In addition to these peaks, other secondary signals were observed with a molecular
mass of 4140.8 Da (IIc) and 4254.0 Da (IIIc). When we analyzed the spectra of the ﬂow-through,
we observed a clear fading of the molecular ion intensities corresponding to the peaks with a mass
of 4198.4 and 4310.3 Da (Figure 2C,D, peaks IIa and IIIa, respectively) as directly compared with the
initial crude extract. However, in this fraction the peak at ~3856 Da stands out (Figure 2D, peak Ib),
representing a peptide without interaction with the CPA immobilized support. To our surprise,
in the fraction eluted from the afﬁnity chromatography, two faded signals not visible in the crude
extract appear in the mass spectra. These two peaks displayed a mass of 4141.5 and 4252.9 Da
(see Figure 2E, peaks IIb and IIIb). In previous studies it has been demonstrated that the puriﬁcation
of carboxypeptidase inhibitors using this resin leads to the hydrolysis of the C-terminal amino acid
present in the targeted inhibitor(s). In the particular case of PCI, a C-terminal glycine residue is usually
cleaved by the immobilized CPA after the binding of the inhibitor [39,40]. This collateral cleavage
causes the loss of 57 Da. This ﬁts with the mass shift observed between the peaks IIa (4198.4 Da) and
IIIa (4310.3 Da) and peaks IIb (4141.5 Da) and IIIb (4252.9 Da) from the afﬁnity chromatography eluates.
It is worth mentioning that the mass discrepancy between the two peaks in either the crude (IIa and
IIIa) or eluates (IIb and IIIb) is 111 Da (Figure 2C,F). This mass difference ﬁts well with the loss of an
N-terminal residue such as glutamic acid or pyroglutamic acid from the miniprotein. The presence of
the latter uncommon amino acid in the inhibitor can be explained by the potential post-translational
cyclization of a Gln. Moreover, the presence of a peak with a mass of 4140.9 Da in the crude extract
(Figure 2C, peak IIc), a mass similar to the molecular mass observed for IIIb (Figure 2F), suggests that
a fraction of the inhibitor without the C-terminal Gly is present in potato tubers.
According to our results, there is a mixture of different molecular species of the inhibitor in the
potato tubers. Some of such species could be derived from post-translational proteolytic cleavage of
either N-terminal or C-terminal amino acids. In addition, an important fraction of the native chuPCI
is suspected to contain as N-terminal a pyroglutamic acid/glutamic acid residue. It is tempting to
hypothesize that such post-translational modiﬁcations (i.e., proteolytic cleavages or the cyclization of
Gln) might play a role in vivo. However, further studies will be needed to conﬁrm this hypothesis.
2.3. Cloning and Sequence Analysis of the Novel Cystine-Knot Metallocarboxypeptidase Inhibitor (chuPCI)
After exploring different sequencing methods, such as peptide mass ﬁngerprint (PMF), Edman
sequencing, or direct sequencing by LC-MS/MS, we did not obtain conclusive results for the sequence
of the native chuPCI. For this reason, we decided to clone the inhibitor directly from the mRNA
of the potato plant for its recombinant production. The total RNA content was isolated from tuber
buds of S. tuberosum subsp. andigenum cv. Churqueña using a commercial kit. The RT-PCR yielded a
359 pb cDNA product. The PCR reaction employed to obtain the speciﬁc cDNA was performed with
specially designed primers from conserved regions of Solanaceae family (see materials and methods
Section 3.6.1 for details). The ampliﬁed cDNA was subjected to multiple sequence alignment using
basic local alignment search tool (BLAST) [41]. This analysis revealed a high degree of similarity
between chuPCI and sequences of members from the PCI family of inhibitors. According to the
MEROPS database, these miniproteins are grouped as the I37 family of protease inhibitors [42]. Direct
DNA sequencing of the resultant cDNA revealed that our sequence shares 96% of sequence identity
with the canonical PCI (S. tuberosum metallocarboxypeptidase inhibitor IIa (PCI) precursor mRNA
(GenBank: NM_001288119.1). The coding sequence of the cDNA (243 bp), which encodes the chuPCI
precursor, has been deposited in the GenBank database (GenBank accession number MF682092).
The nucleotide and deduced amino acid sequences of the chuPCI precursor are presented in Figure 3A.
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3. Nucleotide and e uced amino acid sequ nces of the chuPCI precursor. (A) cDNA of chuPCI
was isolated fr m the RNA of tuber buds from S. tuberosum subsp. andigenum cv. Churqueña, a variety
of Andean potato. The org nization f the primary structure is indicated: r sidues belonging to the
signal peptide (sequences highlighted in yellow); N-terminal pro-segment of the inhibitor (sequences
highlighted in green); mature chuPCI (sequences highlighted in blue and boxed); C-terminal extension
(sequences highlighted in grey). Scissors indicates the speciﬁc post-translational cleavage sites required
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shown unmarked.
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s s ). The same alignment also shows the location of those non-conserved residues b tween
oth inhi itors, which are located in the N-terminal regio of the mature protein. Even though
t e C-terminal regio is directly involved in carboxypeptidase inhibition mechanism, N-terminal
modiﬁcations could produce structural modiﬁc tions that change the stability towards diverse
physicochemical parameters, such stability ag inst temperatur , pH, ionic strength, proteolytic
digestion or differe ces on the inhibition kinetics. As mentioned above, the cystine-knot proteins
are characterized by their compact and stable structure. To conﬁrm that chuPCI has the knottin
scaffold, the sequence of the mature miniprotein was analyzed with the knoter1D predictor from
the KNOTTIN database webpage [43]. As expected, results conﬁrmed that our novel inhibitor is
cystine-knot miniprotein.
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of chuPCI into the pIN-III expression vector with the OmpA3 signal peptide sequence located
at the N-terminal end of th chuPCI sequence ( e Materials and Methods Section 3.6.1 for more details
ab ut the cloning). Then, the vector was transformed inE. coli BL21 (DE3). The expression of chuPCI
was induced by adding IPTG to the culture. After, 20 h of expression at 37 ◦C, t e extrac llular medium
was colle ted and subjected to a disulﬁde reshufﬂing procedure in the p ence of cysteine/cysti e in
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order to ensure a proper folding of the protein. After reshufﬂing, the recombinant protein present in
the clariﬁed supernatant was puriﬁed as described previously for other related inhibitors [20]. Brieﬂy,
recombinant chuPCI (hereafter rchuPCI) was puriﬁed from the clariﬁed supernatant by combining two
different puriﬁcation steps: (1) a mixed-mode Streamline Direct HST adsorbent containing a cationic
ligand; and (2) size-exclusion chromatography (Figure 4). As shown in Figure 4A, elution of rchuPCI
from the mixed-mode chromatography was carried out by applying an increasing gradient of pH = 8.5.
The elution of the recombinant protein was observed when the pH of the elution buffer reached a pH
of ~6.5. Immediately after its elution, all the fractions containing the miniprotein (as determined by
SDS-PAGE and MALDI-TOF analyses) were adjusted concentrated and loaded onto a HiLoad 26/60
Superdex 30 prep grade column to obtain a high-purity product. As shown in Figure 4C, the puriﬁed
rchuPCI showed an apparent electrophoretic mobility in agreement with its theoretical molecular
weight (4325.8 Da).
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Figure 4. Expression and puriﬁcation of the recombinant inhibitor (rchuPCI). rchuPCI was produced
in E. coli. After 20 h expression at 37 ◦C, the recombinant miniprotein from the culture supernatant
subjected to a disulﬁde reshufﬂing procedure. Then, the rchuPCI was puriﬁed from the clariﬁed
supernatant through two puriﬁcation steps: a mixed-mode chromatography with a cation exchange
ligand (Streamline Direct HST) and a gel ﬁltration chromatography (HiLoad 26/60 Superdex 30 prep
grade column). (A) Mixed-mode chromatography elution proﬁle. Protein elution was carried out with
an increasing gradient of phosphate buffer at pH = 8.5 (left Y axis). The green dashed line indicates the
percentage of buffer B (100 mM sodium phosphate buffer at pH 8.5); (B) Size-exclusion chromatography
elution proﬁle of chuPCI. The peak corresponding to the elution of rchuPCI is inidicated (rchuPCI);
(C) Tris-tricine-SDS-PAGE electrophoresis of the puriﬁed rchuPCI. The arrow indicates the location of
the puriﬁed miniprotein; (D) MALDI-TOF mass spectrum of puriﬁed rchuPCI. Numbers above the
major peaks indicate the average masses of the MH+ ion (m/z). Note that the molecular mass is = mass
of the MH+ −1 Da.
MALDI-TOF mas pectrometric analysi of the puriﬁed rchuPCI was carried out. As observ d in
the mass spectra in Figure 4D, rchuPCI displays two major peak with a molecu ar mass of 4308.9 Da
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and 4326.3 Da. The mass of the ﬁrst peak is tightly close to the mass of the major peak present in
the heat-treated crude extract of potato tubers (Figure 2C). The molecular mass of the latter peak ﬁts
with the theoretical molecular weight for rchuPCI of 4325.8 Da. The mass difference between both
peaks is 17 kDa, which ﬁts well with the cyclization of the N-terminal Gln. This conﬁrms the presence
of the N-terminal pyrogluamic acid in the native inhibitor and suggests that this post-translational
modiﬁcation is a common modiﬁcation of the inhibitor that takes place in both plants and during
the recombinant production of the inhibitor. One possible biological role for such modiﬁcation could
be protection against endogenous aminopeptidases, as demonstrated previously for other proteins
and peptides [44,45].
2.5. Determination of the Inhibition Kinetic Constants (Ki) against A/B-Type MCPs
The inhibitory properties of the puriﬁed rchuPCI against bCPA and pCPB were determined and
compared with a recombinant version of the canonical PCI. The Ki values were evaluated following
a pre-steady-state based protocol, according to the Morrison model for tight-binding inhibitors.
All Ki values determined for rchuPCI (summarized in Table 1) were found in the nanomolar range,
a characteristic of such tight-binding inhibitors of MCPs. When compared to the canonical PCI, the Ki
values obtained for rchuPCI against bCPA and pCPB were about 2-fold higher than the Ki values
obtained for recombinant PCI (rPCI). These results suggest that N-terminal modiﬁcations in rchuPCI
lead to an overall decrease in the inhibition potency against the tested MCPs when compared with PCI.
Table 1. Inhibition kinetic constants (Ki) of rPCI and recombinant churqueña PCI (rchuPCI) for bovine
carboxypeptidases A (bCPA) and porcine carboxypeptidases B (pCPB).
Enzyme
rPCI rchuPCI
Ki (nM) Ki (nM)
bCPA a 4.3 ± 0.46 10.8 ± 1.55
pCPB b 10.7 ± 1.17 19.8 ± 1.82
a Measurements were carried using the synthetic substrate N-(4-methoxyphenylazoformyl)-Phe-OH;
b Measurements were carried using the synthetic substrate N-(4-methoxyphenylazoformyl)-Arg-OH.
2.6. Identiﬁcation and De Novo Sequencing of the Native chuPCI
In the present work we have cloned and puriﬁed a novel inhibitor from a variety of Andean
potatoes; S. tuberosum subsp. andigenum cv. Churqueña. By using MALDI-TOF mass spectrometry
we found that the molecular mass of the recombinant inhibitor is similar to the molecular mass
observed for one of the species of the native inhibitor present in potato tubers. However, we were
not able to demonstrate whether our recombinant inhibitor corresponds to the native molecule
identiﬁed in the tubers. To deﬁnitively conﬁrm the sequence and identity of the native molecule we
performed peptide mass ﬁngerprint (PMF). In the past, this technique was successfully used for protein
identiﬁcation of different isoproteins with a high degree of similarity [46,47]. To perform this analysis,
the electrophoretic band corresponding to native chuPCI eluted from the afﬁnity chromatography
(see tris-tricine-SDS-PAGE results in Figure 2B) was cut from the gel and digested with trypsin.
Once extracted, tryptic peptides were analyzed by MALDI-TOF mass spectrometry. The corresponding
mass spectrum for the resultant tryptic peptides is shown in Figure 5. An online MASCOT search
(URL http://www.matrixscience.com) was performed for the identiﬁcation of the tryptic maps against
all the peptide and protein sequences present in the database. However no matches were found for
any of the plant inhibitor or any other known sequences. Nevertheless, a manual search based on
the rchuPCI sequence and considering different post-translational modiﬁcations (i.e., cyclization of
the N-terminal Gln and/or cleavage of the N-terminal and/or C-terminal residues) showed sequence
coverage of 100% (mass error < 50 ppm). As shown in the inset in Figure 5 and Table S1, six tryptic
peptides matched with the theoretical peptides generated from the digestion of different native chuPCI.
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Interestingly, two of the observed tryptic peptides include the N-terminal pyroglutamic acid. This result
allows us to unequivocally conﬁrm the presence of this modiﬁcation in the native chuPCI inhibitor.Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  10 of 19 
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pyroglutamic acid; (III) cleavage of the C-terminal Gly. See Table S1 for more details. The inset shows the
sequence coverage (red arrows) of each peptides from the PMF analysis. The final sequence coverage for
the full-length inhibitor was 97.4% (100% for the C-terminally truncated inhibitor).
Finally, two of theMH+ ions (MH+ ion = 2328.950 andMH+ ion = 1610.778) from the PMF spectrum
were selected for its MALDI-TOF-TOF tandem mass spectrometric fragmentation. The fragmentation
s ectr obtained for the precursor ion MH+ 2328.950 was compared with all the sequences present
in the MASCOT database (consi ering the carbamidomethylation of all Cys). The result from this
search confirmed the expected amino acid seque ce for this peptide (THDDCSGAWFCQACWNSAR)
(Figure S2). The MASCOT search for the fragmentation of the precursor ion MH+ 1610.778 did not
produce results. or this reason, we carried out de novo sequencing of this peptide. The results f t e
sequencing are presented in Figure S3. The sequence deduced from the TOF/TOF analysis corresponds
to the expected sequence for the peptide with an N-terminal pyroglutamic acid (pEQRDPDPICNKPCK).
It is notew rthy to mention that these two peptides together a d up 32 of the 39 chuPCI amino
acids, which stands for 82% sequence coverage. This result strongly supports the presence of the
yroglutamic acid in the N-terminus of the inhibit r. In addition, this result demonstrates that our
cloned inhibitor rchuPCI is lated from Churqueña tuber buds is the same inhibitor that we purified
from the potato extracts (native chuPCI). Taking into account this information, we can now confir
the nat re of all the signals observed in t e MALDI-TOF mass spectra for the affinity-purified ative
c I. As summarized in Table 2, the Churqueña potato extract contains mainly the full-length
chuPCI post-translationally modified with an N-termi al pyroglutamic acid (Figure 2C and signal IIIa
in Table 2). The second most important fractio of the inhibitor (according to its relative intensity in
the mass spectrum) lacks the N-terminal amino acid (signal IIa in Table 2). This suggests the presence
of endogenous active aminopeptidases in the potato tuber that cleaves this residue, and reinforces
the previous hypothesis that the cyclization of the N-terminal Gln might contribute to protecting the
miniprotein from N-terminal proteolytic degradation. The other two minoritarian chuPCI signals
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present in the extract correspond to the chuPCI with or without the N-terminal pyroglutamic acid
residue and lacking the C-terminal Gly (see IIIc and IIc in Table 2).
Table 2. Summary of the different chuPCI molecular species observed in the MALDI-TOF mass
spectrometric analysis of the crude extract and puriﬁed rchuPCI.
Source Signal/Peak Sequence Theor M Obs M Error (ppm)
CE ND QRDPDPICNKPCKTHDDCSGAWFCQACWNSARTCGPYVG 4325.830 - -
CE IIIa pERDPDPICNKPCKTHDDCSGAWFCQACWNSARTCGPYVG 4308.799 4309.313 119
CE IIIc pERDPDPICNKPCKTHDDCSGAWFCQACWNSARTCGPYV- 4251.748 4252.996 293
CE IIa -RDPDPICNKPCKTHDDCSGAWFCQACWNSARTCGPYVG 4197.699 4197.415 −68
CE IIc -RDPDPICNKPCKTHDDCSGAWFCQACWNSARTCGPYV- 4140.647 4139.839 −195
RP rIIIa QRDPDPICNKPCKTHDDCSGAWFCQACWNSARTCGPYVG 4325.830 4325.251 97
RP rIV pERDPDPICNKPCKTHDDCSGAWFCQACWNSARTCGPYVG 4308.799 4307.870 −216
CE, MALDI-TOF mass spectrum of the heat-treated crude extract (see Figure 2C); RP, MALDI-TOF mass spectrum
of puriﬁed recombinant chuPCI (see Figure 4D); ND, Not detected; Theor M, theoretical average mass; error (ppm)
difference between Obs M and Theor M expressed in parts per million. Note that the observed mass corresponds to
the mass of the corresponding MH+ ions +1 Da.
3. Materials and Methods
3.1. Materials and Reagents
Carboxypeptidase A (CPA) from bovine pancreas, Carboxypeptidase B (CPB) from porcine
pancreas, sodium chloride, tris (hydroxymethyl) aminomethane, sodium dodecyl sulphate (SDS),
β-mercaptoethanol (βME), Coomassie Blue G-250, N,N,N0,N0-tetramethyl ethylene diamine
(TEMED), pH range ampholytes and bovine serum albumin were purchased from Sigma-Aldrich
(St. Louis, MO, USA). N-(4-methoxyphenylazoformyl)-phenylalanine-OH potassium salt and N-
(4-methoxyphenylazoformyl)-arginine-OH potassium salt were acquired from Bachem (Bubendorf,
Switzerland). E. coli BL21 (DE3) strain was purchased from Novagen (Madison, WI, USA). pGEM-T
Easy vector was obtained from Promega Corporation (Madison, WI, USA). Primers were synthesized
by Invitrogen Corporation (Carlsbad, CA, USA). DNA Taq polymerase was purchased from Biotools
B&M Labs, S.A. (Madrid, Spain). Restriction enzymes and DNA ladders were obtained from Roche
Applied Science (Penzberg, Germany). DNA T4-ligase was supplied by New England BioLabs (Hitchin,
UK). Pre-stained broad range molecular mass standard was purchased from Invitrogen Corporation.
Solvents and other common reagents were purchased from Sigma-Aldrich.
3.2. Crude Extract Preparation
Tubers of S. tuberosum L., subsp. andigenum cv. Churqueña were obtained from local growers in
Jujuy, Buenos Aires, Argentina. Tubers were kept at−80 ◦C until use. For the crude extract preparation,
approximately 60 g of tubers were thawed at room temperature, peeled and crushed using a blender
after the addition of 170 mL of cooled distilled water. During all the steps, the mixture was kept at low
temperature (4 ◦C) to avoid possible protein denaturation. After achieve a complete homogenization,
starch and other insoluble material were removed by sequential centrifugation. After incubation for
40 min at 4 ◦C, the homogenate was centrifuged (1) for 60 min at 3000× g at 4 ◦C and (2) for 60 min
at 12,000× g at 4 ◦C. Then the clariﬁed supernatant was collected in Eppendorf tubes, centrifuged
at 14,500× g, ﬁltered through Orange Sci PES 0.2 µm ﬁlters and immediately frozen at −80 ◦C
until analysis.
3.3. Total Protein Quantitation
Protein concentration was measured by the Bradford’s assay, as described [48]. Bovine serum
albumin (BSA) was used as standard. Different standard solutions (0, 2, 5, 10, 15, 20 and 25µg·mL−1)
were prepared. 150 µL of each standard solution or test sample were mixed with 150 µL of the
commercial Bradford reagent After 10 min incubation at room temperature the absorbance at 595 nm
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was measured (Tecan Inﬁnite M200 PRO, Männedorf, Switzerland). The protein concentration was
determined by interpolating the absorbance of each sample with the BSA calibration curve.
3.4. Carboxypeptidase A Inhibition Measurements and IC50 Determination
CPA inhibitory activity was determined by using the substrate N-(4-methoxyphenylazoformyl)-
Phe-OH in a 96-well microplate assay [36,49]. Brieﬂy, to determine the inhibitory activity present in the
crude extract, a ﬁxed amount of bovine CPA (50 nM) was pre-incubated with different concentrations
of the extract (ranging from 0 to 300 µg·mL−1) in 0.1 M Tris-HCl buffer (pH 7.5) containing 0.2 M
NaCl. After pre-incubation for 15 min at 37 ◦C, the chromogenic substrate was added to each reaction
mixture at a ﬁnal concentration of 0.1 mM. Immediately, the absorbance at 340 nm was measured every
minute for 15 min. The IC50 value was calculated from the different dose-response curve assays by
ﬁtting the data to the following equation, as previously described [36]:
Y =
100
1+ 10(x−logIC50)
, (1)
where x is the log-transformed protein concentration tested, Y is the relative bCPA activity (% compared
to control condition in the absence of inhibitor). IC50 is the extract concentration required to have 50%
of bCPA inhibition.
The bCPA inhibitory activity of the crude extract and the heat-treated samples was determined
similarly as described above for the determination of the IC50 values. However, in this case a unique
concentration of the sample was tested. bCPA inhibitory activity (%) was calculated by using the
following equation:
Y =
(∆Abs340nm∆t(min) )potato extract
(∆Abs340nm∆t(min) )control
× 100 (2)
The method for tight binding inhibitors was used for the Ki determination [50]. Inhibitory assays
were performed at 25 ◦C under equilibrium conditions ([E0]/Ki ≤ 10) with a ﬁxed concentration
of bCPA or pCPB and substrate (0.1 mM N-(4-methoxyphenylazoformyl)-Phe-OH or 0.1 mM
N-(4-methoxyphenylazoformyl)-Arg-OH, respectively) in Tris-HCl buffer (pH 7.5) containing 0.2 M
NaCl. Samples were pre-incubated for 15 min at RT before the addition of substrate. Then, the decrease
in absorbance was measured at 340 nm in a Victor3 (Perkin Elmer, Boston, MA, USA) plate reader.
Ki values were calculated by direct ﬁtting of the fractional activities ( vi/v0) to the Morrison equation
and assuming a competitive inhibition modality (Equations (3) and (4)).
vi
v0
= 1− ([E]T + [I]T + K
app
i )−
q
([E]T + [I]T + K
app
i )
2 − 4[E]T[I]T
2[E]T
(3)
Ki =
Kappi
([S0/KM]) + 1
(4)
Deﬁnitions are; vi/v0, fractional activity; [E], the total active enzyme concentration; [I], is the
inhibitor concentration; Kappi , apparent inhibition constant; and Ki, true inhibition constant.
3.5. Thermal Stability Experiments and nchuPCI Puriﬁcation by Afﬁnity Chromatography
3.5.1. Thermal Stability Experiments
Aliquots with 1.0 mL of the clariﬁed crude extract (see Section 3.2) where incubated at 60, 70,
85 or 100 ◦C for 60 min. After incubation the samples were centrifuged at 14,500× g for 90 min at 4 ◦C
to eliminate all thermally denatured proteins. Afterwards, the total protein content and the inhibitory
activity of the non-treated crude extract and heat-treated samples were determined.
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3.5.2. Afﬁnity Chromatography Puriﬁcation
A 50 mL aliquot of the clariﬁed crude extract (with a protein concentration of (200 µg·mL−1)
was loaded onto a 2.0 mL bovine CPA-glyoxyl-agarose column prepared in house. The afﬁnity resin
was prepared in house as described [37]. Before the addition of the crude extract, the afﬁnity resin
was previously equilibrated with 10 column volumes (cv) 0.1 M Tris-HCl buffer (pH 7.2) containing
0.2 MNaCl. Then, the column was washed with 5 cv of equilibration buffer. The retained proteins were
eluted with two different buffers: (1) HCl solution with pH = 5.0 (2 cv) and (2) mM HCl solution with
pH = 3.0 (2 cv). The eluted fractions were adjusted immediately to pH 7.0 by adding NaOH. All the
fractions that presented CPA inhibitory activity were pooled and stored at −80 ◦C until analysis.
3.6. Cloning and Expression of rchuPCI
3.6.1. Cloning and Sequence Analysis of chuPCI
Total RNA from S. tuberosum L. subsp. andigenum cv. Churqueña tuber buds was extracted
using the RNeasy Plant Mini Kit (Qiagen, Hannover, Germany). In order to synthesize
ﬁrst-strand cDNA, a reverse transcription reaction was done using RoR1poli-(dT)15 primer
(50-CCGGAATTCACTGCAGGGTACCCAATACGACTCACTATAGGGCTTTTTTTTTTTTTTTTT-30)
and M-MuLV enzyme (Fermentas, Waltham, MA, USA).
The PCR speciﬁc primers (Fwd: 50-ATTCTCCTTGTGGTTATTGCTGC-30 and Rev:
50-GCCACAAAGCATGTATCTAAGAC-30) were designed based on conserved regions between
cDNAs encoding carboxypeptidase inhibitor precursors in S. tuberosum subsp. tuberosum L. (GenBank:
NM_001288119.1) and S. lycopersicum L. (GenBank: NM_001247005.2). The resultant cDNA was cloned
into the pGEM-T Easy vector (Promega). The DNA construct was named pGEM_chuPCIprecursor.
The sequence construct was sequenced by automatic DNA sequencing (Macrogen Inc., Seoul, Korea)
and the resultant sequence for the chuPCI cDNA was deposited in the GenBank database (accession
code MF682092).
3.6.2. Expression and Puriﬁcation of rchuPCI
The nucleotide sequence corresponding to the mature chuCPI (39 amino acids) was cloned into
the expression vector pIN-III-OmpA3. The sequence for the OmpaA3 signal peptide was cloned
into the N-terminal region of the inhibitor. The OmpA3 sequence was included to promote the
secretion of the protein to the periplasm of the bacteria in order to facilitate the proper folding of the
miniprotein. The sequence of chuPCI was ampliﬁed by PCR and was inserted in the pIN-III-OmpA3
vector between the restriction sites for XbaI and SalI present in the expression vector. Previously,
the N-terminal sequence (including the OmpA3 sequence) was introduced by PCR-mediated extension.
The extension of the OmpA3 sequence was performed similarly, as described by Lufrano et al [20].
In our case the primers were: Fwd_1: 50-CTACCGTAGCGCAGGCCCAGCGAGACCCGGATCC-30,
Fwd_2: 50-GCTATCGCGATTGCAGTGGCACTGGCTGGTTTCGCTACCGTAGCGCAGGCC-30,
Fwd_3: 50-tctagaTAACGAGGGCAAAAAATGAAAAAGACAGCTATCGCGATTGCAGTGGC-30,
Rev: 50-GTCAGAATTCCTAGCCAACATAGGGCCCACATG-30. The resultant pIN-III-OmpA3
construct was transformed into E. coli BL21 (DE3).
Recombinant protein expression was carried out as previously described for other potato
inhibitors [20]. In brief, 1 L culture of E. coli BL21 (DE3) transformed with the construct was grown
at 37 ◦C in LB medium containing 100 µg·mL−1 ampicillin (Amp) until it reached an absorbance at
600 nm of about 0.6. The expression of rchuPCI was induced by adding 0.2 mM IPTG to the cell culture.
After 20 h incubation at 37 ◦C, the extracellular medium was collected and subjected to a disulﬁde
reshufﬂing procedure in the presence of a mixture of cysteine/cystine (ﬁnal concentrations of 4 and
2 mM, respectively). This step is essential to ensure proper folding of the recombinant protein [20,51].
After reshufﬂing, the sample was clariﬁed by overnight incubation at 4 ◦C and pH 4.0 and then,
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puriﬁed as described previously for other related inhibitors [20]. After reshufﬂing, the pH of the
solution was adjusted to pH 8.5 and the sample was incubated for 4 h at 4 ◦C.
After incubation, the rchuPCI was puriﬁed. Prior to puriﬁcation, the pH of the medium was
adjusted to pH = 4 with 1M citric acid. Then, the sample was incubated for overnight at 4 ◦C.
After centrifugation at 12,000× g for 25 min, the clariﬁed supernatant was ﬁltered through 0.45 µm
ﬁlters and applied onto a mixed-mode exchange column (Streamline Direct HST, GE Healthcare
Biosciences, Uppsala, Sweden). The column was previously equilibrated with 100 mM sodium citrate
buffer (pH 3.5). rchuPCI was eluted from the column by applying an increasing linear gradient of
100 mM sodium phosphate buffer (pH 8.5). The eluates containing the inhibitor (as determined by
tris-tricine-SDS-PAGE and MALDI-TOF measurements) were pooled, concentrated and loaded onto a
HiLoad 26/60 Superdex 30 prep grade column (GE Healthcare). The elution of rchuPCI was carried
out with an isocratic gradient of 10 mM phosphate buffer (pH 8.5) at a ﬂow rate of 2.5 mL min−1.
Finally, all the eluted fractions containing rchuPCI were pooled and concentrated using an Amicon
Ultra 3 kDa centrifugal device (Millipore, Darmstadt, Germany). The protein concentration was
determined by measuring the absorbance at 280 nm and assuming a theoretical extinction coefﬁcient
of 12,865 M−1·cm−1 [52].
3.7. General Characterization of Methods
3.7.1. Tris-Tricine-SDS-PAGE
Tris-tricine-SDS-PAGE was used to determine the purity of the protease inhibitor during the
different puriﬁcation steps. In addition, this technique was used to analyze the protein composition
of the potato crude extracts and heat-treated samples. Brieﬂy, samples were subjected to denaturing
electrophoresis in tris-tricine gels composed of a stacking gel (4% T, 3% C), a spacer gel (10% T, 3% C)
and a separating gel (16.5% T, 6% C), which is especially suitable to resolve peptide mixtures [53].
Samples were mixed with NovexTM tricine SDS Sample buffer (2×) and were incubated for
5 min at 95 ◦C. The electrophoresis was performed in a Mini-Protean III dual slab cell (Bio-Rad,
Hercules, CA, USA). The voltage was kept constant (30 V) until the samples completely left the
stacking gel, and then the voltage was increased up to 90 V. The voltage was maintained constant
until the end of the chromatography. Gels were stained with 0.2% Coomassie Brilliant Blue G-250
(Sigma-Aldrich, St. Louis, MO, USA) for overnight.
3.7.2. Isoelectrofocusing (IEF)
IEF was used to determine the isoelectric point of the native chuPCI inhibitors present in the
crude extract and heat-treated samples. To perform the analysis, all the samples were previously
desalted. Desalting of samples was achieved by adding ﬁve volumes of acetone to the samples.
After centrifugation at 16,000× g, the insoluble pellet was dissolved in a ﬁxed volume of distilled water.
Then, samples were loaded onto polyacrylamide gels (5%) containing broad pH range ampholytes
(Pharmalyte 3–10, Pharmacia, Lisbon, Portugal). Isoelectric focusing was carried out in a Mini IEF
Cell (Model 111, Bio-Rad) under constant voltage conditions in three different steps (step 1: 100 V for
30 min, step 2: 200 V for 15 min and step 3: 450 V for 60 min). Gels were then ﬁxed and stained with a
0.2% Coomassie Brilliant Blue G-250 solution.
3.7.3. MALDI-TOF Mass Spectrometric Analysis
For MALDI-TOF mass spectrometric analysis, samples from the different purification steps, as well
as from the clarified crude extract were mixed with an equal volume of α-cyano-4-hydroxycinnamic
acid (hcca) matrix solution. Previously, the samples were desalted by dialysis in 0.022 µm filters.
The matrix-sample mixture was spotted onto MT 384 target plate polished steel T F from Bruker Daltonics,
and the spots were evaporated to dryness at room temperature. Mass spectra were acquired on a
Bruker Daltonics Ultraflextreme MALDI-TOF mass spectrometer (Bruker Daltonics, Billerica, MA, USA)
Int. J. Mol. Sci. 2018, 19, 678 15 of 19
operating in a linear positive mode. PMF analysis was performed for the identification of nchuPCI.
In brief, an in situ tryptic digestion of the tris-tricine-SDS-PAGE electrophoresis bands as performed
by following a well described protocol [46]. The resultant tryptic peptides were dissolved in 10 µL
of 0.1% CF3CO2H (v/v) an analyzed by MALDI-TOF in the presence of hcca matrix. Mass spectra
of the tryptic peptides were acquired in a reflectron positive mode with 25 kV acceleration voltage.
In both cases, external calibrations were performed by using standard peptide calibration mixtures
from Bruker Daltonics. Two precursor ions MH+ (1610.778 and 2328.950) were subjected to TOF-TOF
fragmentation. The resultant fragmentation spectra for these precursor MH+ ions were compared with
all the fragmentation patters for all the sequences present in the MASCOT database (considering the
carbamidomethylation of all Cys). In addition, de novo sequencing of the fragmentation pattern for the
ion MH+ 1610.778 was carried out using BioTools software (version 3.2, Bremen, Germany).
4. Conclusions
In the present study, a novel A/B-type metallocarboxypeptidase inhibitor from S. tuberosum subsp.
andigenum cv. Churqueña (chuPCI) was cloned, expressed, puriﬁed, and thoroughly characterized.
chuPCI has natural mutations in three N-terminal residues when compared with prototype molecule
of the PCI-family of inhibitors (PCI from S. tuberosum subsp. tuberosum). Kinetic measurements for the
recombinant inhibitor showed lower Ki values against both bCPA and pCPB in comparison with the
canonical PCI. By using MALDI-TOF mass spectrometry and direct comparison between the native
and recombinant forms, four species of the carboxypeptidase inhibitor were identiﬁed in the crude
extract of the Churqueña tubers. The sequence of these molecular species was conﬁrmed by PMF
MALDI-TOF MS/MS and de novo sequencing. One of these variants corresponds to chuPCI with an
N-terminal pyroglutamic acid. This little-studied modiﬁcation results from the cyclization of ﬁrst Gln
residue. The second majoritarian signal corresponds to chuPCI without the pyroglutamic acid at the
N-terminus, and the third and fourth forms correspond to chuPCI with or without the N-terminal
pyroglutamic acid both lacking the C-terminal Gly.
It is important to remark that in this work we were able to clone a novel inhibitor present in a
singular variety of Andean potatoes, and this recombinant protein was the same as is present in large
amounts in the tubers. We combined two different approaches to demonstrate the presence of this novel
inhibitor in the tubers: molecular biology and mass spectrometric analysis. The combination of these two
strategies allowed us to unravel the complexity of chuPCI variants present in Churqueña potato tubers,
thus contributing to increased knowledge about natural MCPIs. In addition, our work contributes to
increase the repertoire of bioactive cystine-knot miniproteins isolated from natural sources, which are
potentially useful for biomedical applications. Moreover, our thorough characterization of the native
inhibitor using mass spectrometry allowed us to identify the presence of post-translational modifications
(i.e., the cyclization of the N-terminal Gln and N- and C-terminal proteolysis) not detectable by other
conventional techniques.
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CKMPs Cystine-knot miniproteins
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MCPs Metallocarboxypeptidases
PPIs Protease peptide inhibitors
PCI Potato carboxypeptidase inhibitor
ACI Ascaris suum carboxypeptidase inhibitor
LCI Hirudo medicinalis carboxypeptidase inhibitor
TCI Ticks carboxypeptidase inhibitor
H1TCI Hemaphysalis longicornis carboxypeptidase inhibitor
NvCI Nerita versicolor carboxypeptidase inhibitor
ECI Endogenous carboxypeptidase inhibitor
SmCI Sabellastarte magniﬁca carboxypeptidase inhibitor
CPA Carboxypeptidase A
CPB Carboxypeptidase B
SDS Sodium dodecyl sulfate
βME β-Mercaptoethanol
TEMED N,N,N0,N0-Tetramethyl ethylene diamine
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